|CAS No.||112522-64-2||Synonyms||PD-123654, GOE-5549, Acetyldinaline|
|Solubility (25°C) *||In vitro||DMSO||54 mg/mL (200.51 mM)|
|In vivo||5% DMSO+40% PEG 300+ddH2O||5mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Chemical Name||Benzamide, 4-(acetylamino)-N-(2-aminophenyl)-|
|Description||Tacedinaline (CI994) is a selective class I HDAC inhibitor with IC50 of 0.9, 0.9, 1.2, and >20 μM for human HDAC 1, 2, 3, and 8, respectively. Phase 3.|
|In vitro||CI-994 (< 160 mM) shows cytostatic effect with concomitant increase at G0/G1 phase, a reduction at S phase level and increased apoptosis in A-549 and LX-1 cells.  CI-994 inhibits growth of LNCaP cell with IC50 of 7.4 μM.  CI-994 exerts activity against several tumor cell lines with greater cytotoxicity against the solid tumors relative to both the leukemia and normal fibroblast cell lines.  CI-994 inhibits growth of rat leukemia BCLO cells with IC50 of 2.5 μM. |
|In vivo||CI-994 exerts demonstrated antitumor activity against several tumor models, including the chemo-resistant mouse pancreatic ductal carcinoma as well as the human prostate tumor model LNCaP. |
|Cell lines||LNCaP cell lines|
|Incubation Time||2-4 days|
LNCaP cell lines are maintained in RPMI 1640 medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, as the complete culture medium. Cells (2×104) are seeded in 24-well plates and incubated in a 5% CO2 incubator at 37 °C for 1 day. Cultures are treated with CI-994, alone and in combination on day 2 and 4. Cells are washed on day 2 and 4 and media are changed. Mitochondrial metabolism is measured as a marker for cell growth by adding 100 μL/well MTT (5 mg/mL in medium) with 2 hours incubation at 37 °C on Day 6. Crystals formed are dissolved in 500 μL of DMSO. The absorbance is determined using a microplate reader at 560 nm. The absorbance data are converted into cell proliferation percentage. Each assay is performed in triplicate.
|Animal Models||human prostate tumor model LNCaP|
|Formulation||5% ethanol, 1% P.O.E. and 94% dH20|
|Administration||Administered via oral gavage|
Acetylation site specificities of lysine deacetylase inhibitors in human cells. [Scholz C, et al. Nat Biotechnol, 2015, 10.1038/nbt.3130]PubMed: 25751058
A substrate-independent TR-FRET histone deacetylase inhibitor assay. [Marks BD, et al. J Biomol Screen, 2011, 16(10):1247-53]PubMed: 21940713
PLEASE KEEP THE PRODUCT UNDER -20°C FOR LONG-TERM STORAGE.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.